SIGA (SIGA) 10-K 3 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Feb. 16, 2022	Jun. 30, 2021
Document Information [Line Items]
Entity Central Index Key	0001010086
Entity Registrant Name	Siga Technologies INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	0-23047
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3864870
Entity Address, Address Line One	31 East 62nd Street
Entity Address, Postal Zip Code	10065
Entity Address, City or Town	New York
Entity Address, State or Province	NY
City Area Code	212
Local Phone Number	672-9100
Title of 12(b) Security	common stock, $.0001 par value
Trading Symbol	SIGA
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 313,533,032
Entity Common Stock, Shares Outstanding		73,029,902
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Florham Park, New Jersey
Auditor Firm ID	238
ICFR Auditor Attestation Flag	true

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 103,138,819	$ 117,890,240
Accounts receivable	83,650,450	3,340,263
Inventory	19,510,379	20,265,519
Prepaid expenses and other current assets	2,453,444	2,112,069
Total current assets	208,753,092	143,608,091
Property, plant and equipment, net	2,365,957	2,103,990
Deferred tax asset, net	2,422,607	2,544,053
Goodwill	898,334	898,334
Other assets	286,585	676,923
Total assets	214,726,575	149,831,391
Current liabilities
Accounts payable	2,028,004	1,278,217
Accrued expenses and other current liabilities	9,252,812	8,285,738
Income tax payable	19,207,042	919,555
Total current liabilities	30,487,858	10,483,510
Warrant liability	6,521,441	6,639,211
Other liabilities	3,402,869	2,915,401
Total liabilities	40,412,168	20,038,122
Commitments and contingencies (Note 13)
Stockholders' equity
Common stock ($.0001 par value, 600,000,000 shares authorized, 73,543,602 and 77,195,704 issued and outstanding at December 31, 2021 and December 31, 2020, respectively)	7,354	7,720
Additional paid-in capital	226,070,308	224,978,430
Accumulated deficit	(51,763,255)	(95,192,881)
Total stockholders' equity	174,314,407	129,793,269
Total liabilities and stockholders' equity	$ 214,726,575	$ 149,831,391

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	73,543,602	77,195,704
Common stock, shares outstanding (in shares)	73,543,602	77,195,704

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues
Total revenues	$ 133,670,454	$ 124,959,304	$ 26,742,085
Operating expenses
Cost of sales and supportive services	16,601,880	14,797,419	1,782,838
Selling, general and administrative	17,323,429	14,003,184	13,252,136
Research and development	9,942,194	10,938,930	13,303,149
Patent expenses	710,152	719,141	726,105
Total operating expenses	44,577,655	40,458,674	29,064,228
Operating income (loss)	89,092,799	84,500,630	(2,322,143)
Gain (loss) from change in fair value of warrant liability	117,770	(3,525,846)	5,091,256
Loss on extinguishment of Term Loan	0	(4,981,461)	0
Interest expense	0	(3,016,817)	(15,769,768)
Other income, net	101,172	532,085	2,822,232
Income (loss) before income taxes	89,311,741	73,508,591	(10,178,423)
(Provision) benefit for income taxes	(19,860,975)	(17,166,581)	2,937,276
Net and comprehensive income (loss)	$ 69,450,766	$ 56,342,010	$ (7,241,147)
Basic earnings (loss) per share (in dollars per share)	$ 0.92	$ 0.71	$ (0.09)
Diluted earnings (loss) per share (in dollars per share)	$ 0.91	$ 0.71	$ (0.15)
Weighted average shares outstanding: basic (in shares)	75,322,194	79,259,000	81,031,254
Weighted average shares outstanding: diluted (in shares)	76,402,716	79,437,306	82,175,023
Product Sales and Supportive Services [Member]
Revenues
Total revenues	$ 126,802,536	$ 115,471,071	$ 11,190,064
Research and Development [Member]
Revenues
Total revenues	$ 6,867,918	$ 9,488,233	$ 15,552,021

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity / (Deficiency) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2018	80,763,350
Balance at Dec. 31, 2018	$ 8,076	$ 218,697,872	$ (115,791,261)	$ 0	$ 102,914,687
Net income (loss)			(7,241,147)		(7,241,147)
Issuance of common stock upon exercise of stock options (in shares)	9,769
Issuance of common stock upon exercise of stock options	$ 1	(1)			0
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights (in shares)	515,888
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights	$ 52				0
Issuance of common stock upon vesting of RSUs and exercise of stock-settled appreciation rights		(52)
Issuance of common stock to employees (in shares)	53,332
Issuance of common stock to employees	$ 5	(5)			0
Issuance of common stock upon exercise of warrants (in shares)	159,782
Issuance of common stock upon exercise of warrants	$ 16	1,172,785			1,172,801
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)	(232,253)
Payment of common stock tendered for employee stock-based compensation tax obligations	$ (23)	(1,176,556)			(1,176,579)
Stock-based compensation		2,113,994			2,113,994
Balance (in shares) at Dec. 31, 2019	81,269,868
Balance at Dec. 31, 2019	$ 8,127	220,808,037	(123,032,408)	0	97,783,756
Net income (loss)			56,342,010		56,342,010
Issuance of common stock upon exercise of stock options (in shares)	11,822
Issuance of common stock upon exercise of stock options	$ 1				0
Issuance of common stock upon exercise of warrants (in shares)	393,646
Issuance of common stock upon exercise of warrants	$ 40	3,003,477			3,003,517
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)	(29,035)
Payment of common stock tendered for employee stock-based compensation tax obligations	$ (3)	(184,013)			(184,016)
Stock-based compensation		1,350,948			1,350,948
Repurchase of common stock (in shares)	(4,628,473)
Repurchase of common stock	$ (463)		(28,502,483)		(28,502,946)
Issuance of common stock upon exercise of stock options		(1)
Issuance of common stock upon vesting of RSUs (in shares)	177,876
Issuance of common stock upon vesting of RSUs	$ 18	(18)			0
Balance (in shares) at Dec. 31, 2020	77,195,704
Balance at Dec. 31, 2020	$ 7,720	224,978,430	(95,192,881)	0	129,793,269
Net income (loss)			69,450,766		$ 69,450,766
Issuance of common stock upon exercise of stock options (in shares)					0
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)	(27,295)
Payment of common stock tendered for employee stock-based compensation tax obligations	$ (3)	(173,915)			$ (173,918)
Stock-based compensation		1,265,809			1,265,809
Repurchase of common stock (in shares)	(3,787,683)
Repurchase of common stock	$ (379)		(26,021,140)		(26,021,519)
Issuance of common stock upon vesting of RSUs (in shares)	162,876
Issuance of common stock upon vesting of RSUs	$ 16	(16)			0
Balance (in shares) at Dec. 31, 2021	73,543,602
Balance at Dec. 31, 2021	$ 7,354	$ 226,070,308	$ (51,763,255)	$ 0	$ 174,314,407

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net income (loss)	$ 69,450,766	$ 56,342,010	$ (7,241,147)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and other amortization	522,368	529,814	526,997
(Gain) loss on change in fair value of warrant liability	(117,770)	3,525,846	(5,091,256)
Stock-based compensation	1,265,809	1,350,948	2,113,994
Write down of inventory, net	618,771	0	0
Deferred income taxes provision (benefit)	121,446	11,606,949	(2,417,617)
Loss on extinguishment of Term Loan	0	4,981,461	0
Non-cash interest expense	0	887,132	4,497,271
Changes in assets and liabilities:
Accounts receivable	(80,310,187)	827,733	(2,208,863)
Inventory	136,369	(8,009,992)	(6,744,644)
Prepaid expenses and other assets	48,963	699,102	(714,272)
Accounts payable, accrued expenses and other liabilities	986,865	(3,116,843)	936,839
Income tax payable	18,287,487	912,462	0
Deferred revenue	483,749	982,606	(1,861,605)
Net cash provided by (used in) operating activities	11,494,636	71,519,228	(18,204,303)
Cash flows from investing activities:
Capital expenditures	(50,620)	(15,501)	(29,094)
Cash used in investing activities	(50,620)	(15,501)	(29,094)
Cash flows from financing activities:
Payment of employee tax obligations for common stock tendered	(173,918)	(184,016)	(1,176,579)
Repurchase of common stock	(26,021,519)	(28,502,946)	0
Repayment of Term Loan	0	(85,913,459)	0
Cash used in financing activities	(26,195,437)	(114,600,421)	(1,176,579)
Net decrease in cash and cash equivalents	(14,751,421)	(43,096,694)	(19,409,976)
Cash, cash equivalents and restricted cash at the beginning of period	117,890,240	160,986,934	180,396,910
Cash, cash equivalents and restricted cash at end of period	103,138,819	117,890,240	160,986,934
Supplemental disclosure of cash flows information:
Non-cash lease right-of-use asset and associated liability (net of deferred rent in 2019)	733,715	0	2,944,932
Conversion of warrant to common stock	0	3,003,517	1,172,801
Issuance of common stock upon cashless exercise	0	97,250	118,500
Cash income taxes paid (refund), net	$ 1,063,744	$ 3,718,581	$ (1,276,129)

Note 1 - Organization and Basis

Note 1 - Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Basis of Presentation Description of Business SIGA Technologies, Inc. (“SIGA” or the “Company”) is a commercial-stage pharmaceutical company. The Company's lead product, TPOXX® (“oral TPOXX®”) is a United States Food & Drug Administration ("FDA")-approved oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. On July 13, 2018, Oral TPOXX® is a novel, patented drug that is easy to store, transport and administer. Oral TPOXX® labeling, approved by the FDA, limits sales of oral TPOXX® in the U.S. to those for the U.S. Strategic National Stockpile ("Strategic Stockpile"). The Company has been delivering oral TPOXX® to the Strategic Stockpile since 2013. On December 1, 2021, On January 10, 2022, With respect to the regulatory approvals by Health Canada and the EMA, oral tecovirimat represents the same formulation that was approved by the FDA in July 2018

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the periods reported. The most significant estimates include the variables used in the calculation of fair value of warrants granted or issued by the Company, reported amounts of revenue, and the valuation of deferred tax assets. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary. Actual results could differ from these estimates. Basis of Presentation The consolidated financial statements and related disclosures are presented in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and reflect the consolidated financial position, results of operations and cash flows for all periods presented. Cash Equivalents The Company considers all highly liquid investments with original maturities of three Restricted Cash and Cash Equivalents Cash and cash equivalents held in restricted accounts were available to pay interest, fees and principal related to the Term Loan (see Note 7 March 13, 2020, second 2020. December 31, 2021 2020. The following table reconciles cash, cash equivalents and restricted cash per the consolidated statements of cash flows to the consolidated balance sheet for each respective period: As of December 31, 2019 2018 Cash and cash equivalents $ 65,249,072 $ 100,652,809 Restricted cash - short-term 95,737,862 11,452,078 Restricted cash - long-term — 68,292,023 Cash, cash equivalents and restricted cash $ 160,986,934 $ 180,396,910 Concentration of Credit Risk The Company has cash in bank accounts that exceeds the Federal Deposit Insurance Corporation insured limits. The Company has not no Accounts Receivable Accounts receivable are recorded net of provisions for doubtful accounts. At December 31, 2021 2020 December 31, 2021 2020 Inventory Inventory is stated at the lower of cost or net realizable value. The cost is determined using the first first may no Property, Plant and Equipment Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation and amortization are provided on a straight-line method over the estimated useful lives of the various asset classes. The estimated useful lives are as follows: five three seven Warrant Liability The Company accounts for warrants in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain cash settlement features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Fair value is estimated using model-derived valuations. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities. Revenue Recognition All of the Company’s revenue is derived from long-term contracts that span multiple years. The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers 606” Performance Obligations 606. December 31, 2021 Note 3 five two one Contract modifications may not The Company’s performance obligations are satisfied over time as work progresses or at a point in time. All of the Company’s revenue related to current research and development performance obligations is recognized over time, because the customer simultaneously receives and consumes the benefits provided by the services as the Company performs these services. The Company recognizes revenue related to these services based on the progress toward complete satisfaction of the performance obligation and measures this progress under an input method, which is based on the Company’s cost incurred relative to total estimated costs. Under this method, progress is measured based on the cost of resources consumed (i.e., cost of third third Contract Estimates Contract estimates are based on various assumptions to project the outcome of future events that often span multiple years. These assumptions include: labor productivity; the complexity of the work to be performed; external factors such as customer behavior and potential regulatory outcomes; and the performance of subcontractors, among other variables. The nature of the work required to be performed on many of the Company’s performance obligations and the estimation of total revenue and cost at completion are complex, subject to many variables and require significant judgment. The consideration associated with research and development services is variable as the total amount of services to be performed has not not A significant change in one Contract Balances may December 31, 2021 December 31, 2021 Remaining Performance Obligations not December 31, 2021 three Leases The Company accounts for leases in accordance with ASC 842, Leases 842” Adoption of ASC 842 January 1, 2019, 842 first second 2019, first 842 January 1, 2019 The Company determines if an arrangement is a lease at inception. Leases with an initial term less than one not one Operating lease liabilities are recognized at the commencement date based on the present value of future minimum lease payments over the lease term. ROU assets are recognized based on the corresponding lease liabilities adjusted for qualifying initial direct costs, prepaid or accrued lease payments and unamortized lease incentives. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease. Lease terms may Research and Development Research and development expenses include costs directly and indirectly attributable to the conduct of research and development programs, and performance pursuant to certain customer contracts, including employee related costs, materials, supplies, depreciation on and maintenance of equipment, the cost of services provided by outside contractors, including services related to the Company’s clinical trials and facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred. Costs related to the acquisition of technology rights, for which development work is still in process, and that have no Goodwill The Company evaluates goodwill for impairment at least annually or as circumstances warrant. The impairment review process compares the fair value of the reporting unit in which goodwill resides to its carrying value. The Company operates as one one Share-based Compensation Stock-based compensation expense for all share-based payment awards made to employees and directors is determined on the grant date; for option awards, fair value was estimated using the Black-Scholes model. These compensation costs are recognized net of an estimated forfeiture rate over the requisite service periods of the awards. Forfeitures are estimated on the date of the respective grant and revised if actual or expected forfeiture activity differs from original estimates. The fair value of cash-settled restricted stock unit ("RSU") awards is determined by the value of our common stock and is recognized based on the portion of the requisite service period satisfied as of each valuation date. The fair valuation of the cash-settled awards changes based on changes in our common stock price. The portion of cash-settled RSUs that is recognized based on service period is reflected in accrued expenses and other current liabilities in our consolidated balance sheet. Increases (or decreases) in accrued expenses result in adjustments to earnings for the associated valuation updates. Income Taxes The Company recognizes income taxes utilizing the asset and liability method of accounting for income taxes. Under this method, deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities at enacted tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is established if it is more likely than not not may not fifty not Repurchase of shares When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, is recognized as a deduction from equity. The excess of the purchase price above par value of repurchased shares that are retired is presented as an increase to accumulated deficit (or a reduction of retained earnings, if any). Earnings (Loss) per Share Basic earnings per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period, assuming potentially dilutive common shares from option exercises, RSUs, warrants and other incentives had been issued and any proceeds received in respect thereof were used to repurchase common stock at the average market price during the period. The assumed proceeds used to repurchase common stock is the sum of the amount to be paid to the Company upon exercise of options and warrants and the amount of compensation cost attributed to future services not Fair Value of Financial Instruments The carrying value of cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximates fair value due to the relatively short maturity of these instruments. Common stock warrants which are classified as liabilities are recorded at their fair market value as of each reporting period. The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy: • Level 1 • Level 2 not • Level 3 third The Company uses model-derived valuations where certain inputs are unobservable to third 3. There were no 2021 2020 December 31, 2021 December 31, 2020 1 no 2 December 31, 2021 December 31, 2020 The following table presents changes in the liability-classified warrant measured at fair value using Level 3 Fair Value Measurements of Level 3 liability-classified warrant Warrant liability at December 31, 2020 $ 6,639,211 Decrease in fair value of warrant liability (117,770 ) Exercise of warrants — Warrant liability at December 31, 2021 $ 6,521,441 Loss Contingencies The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no Segment Information The Company is managed and operated as one not not one Recent Accounting Pronouncements In December 2019, No. 2019 12, Simplifying the Accounting for Income Taxes December 15, 2020, first 2021 no

Note 3 - Procurement Contracts

Note 3 - Procurement Contracts and Research Agreements	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Procurement Contract and Research Agreements [Text Block]	3. 19C On September 10, 2018, December 31, 2021 "19C five $239.7 September 7, 2021 may ten 19C The base period of performance specifies potential payments of approximately $51.7 million for the following activities: payments of approximately $11.1 million for the delivery of approximately 35,700 courses of oral TPOXX® to the Strategic Stockpile; payments of $8.0 million for the manufacture of 20,000 courses of final drug product of IV TPOXX® ("IV FDP"), of which $3.2 million of payments are related to the manufacture of bulk drug substance ("IV BDS") to be used in the manufacture of IV FDP; payments of approximately $32.0 million to fund advanced development of IV TPOXX®; and payments of approximately $0.6 million for supportive procurement activities. As of December 31, 2021 December 31, 2021 December 31, 2020 The options that have been exercised to date provide for payments up to approximately $239.7 million. There are exercised options for the following activities: payments up to $11.2 million for the procurement of raw materials used in the 2020 December 31, 2021 2021 December 2021, January 2022); Unexercised options specify potential payments up to approximately $311.1 million in total (if all such options are exercised). There are options for the following activities: payments of up to $225.1 million for the delivery of oral TPOXX® to the Strategic Stockpile; payments of up to $76.8 million for the manufacture of courses of IV FDP, of which up to $30.7 million of payments would be paid upon the manufacture of IV BDS to be used in the manufacture of IV FDP; payments of up to approximately $3.6 million to fund post-marketing activities for IV TPOXX®; and payments of up to approximately $5.6 million for supportive procurement activities. The options related to IV TPOXX® are divided into two may none 19C three three not 64,000 Revenues in connection with the 19C 19C December 31, 2021 2020 December 31, 2021 2020 1C 2011 On May 13, 2011, "1C "2011 The 1C December 31, 2021 The 1C December 2024. Remaining performance obligations under the 1C December 31, 2021 2020 December 31, 2021. December 31, 2020, International Procurement Contracts On January 13, 2021, five January 2022, March 31, 2023; March 31, 2023 December 31, 2021, first six 2021. On April 3, 2020, four second 2020, third 2021, The PHAC and CDND contract awards were both coordinated between SIGA and Meridian under the international promotion agreement, as amended (the "International Promotion Agreement") that was entered into by the parties on June 3, 2019. Under the terms of the International Promotion Agreement, Meridian was granted exclusive rights to market, advertise, promote, offer for sale, or sell oral TPOXX® in a field of use specified in the International Promotion Agreement in all geographic regions except for the United States (the “Territory”), and Meridian has agreed not The fee Meridian retains pursuant to the International Promotion Agreement is a specified percentage of the collected proceeds of sales of oral TPOXX® net of certain expenses, for years in which customer invoiced amounts net of such expenses are less than or equal to a specified threshold, and a higher specified percentage of such collected net proceeds for years in which such net invoiced amounts exceed the specified threshold. Revenue in connection with international procurement contracts for the delivery of product are recognized at a point in time on a gross basis, as the Company acts as the principal in the transaction. During the year ended December 31, 2021 December 31, 2020 Research Agreements and Grants The Company has an R&D program for IV TPOXX®. This program is funded by the 19C February 2024. December 31, 2021 December 31, 2021 2020 In July 2019, April 30, 2024. December 31, 2021 December 31, 2021 2020 Contracts and grants include, among other things, options that may may not may not

Note 4 - Inventory

Note 4 - Inventory	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	4. Inventory Inventory consisted of the following: As of December 31, 2021 December 31, 2020 Raw materials $ 22,047 $ 2,628,153 Work in-process 17,453,358 15,415,425 Finished goods 2,034,974 2,221,941 Inventory $ 19,510,379 $ 20,265,519 For the year ended December 31, 2021,

Note 5 - Property, Plant and Eq

Note 5 - Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property, Plant and Equipment Property, plant and equipment consisted of the following: As of December 31, 2021 December 31, 2020 Leasehold improvements $ 2,420,028 $ 2,420,028 Computer equipment 511,062 532,125 Furniture and fixtures 377,859 377,859 Operating lease right-of-use asset 3,678,647 2,944,932 6,987,596 6,274,944 Less-accumulated depreciation (4,621,639 ) (4,170,954 ) Property, plant and equipment, net $ 2,365,957 $ 2,103,990 Depreciation and amortization expense on property, plant, and equipment was $0.5 million for each of the years ended December 31, 2021 2020 2019

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Accrued Expenses and Other Liabilities [Text Block]	6. Accrued Expenses Accrued expenses and other current liabilities consisted of the following: As of December 31, 2021 December 31, 2020 Deferred revenue $ 3,764,696 $ 3,280,947 Compensation 2,811,700 2,933,738 Other 558,362 486,158 Professional fees 527,026 251,824 Inventory 488,081 150,349 Lease liability, current portion 466,830 449,940 Vacation 379,720 405,176 Research and development vendor costs 256,397 327,606 Accrued expenses and other current liabilities $ 9,252,812 $ 8,285,738

Note 7 - Debt

Note 7 - Debt	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	7. On March 13, 2020, December 31, 2020, On September 2, 2016, November 16, 2016 The Term Loan had a maturity date on the earliest to occur of (i) the four

Note 8 - Per Share Data

Note 8 - Per Share Data	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	8. Per Share Data The Company computes, presents and discloses earnings per share in accordance with the authoritative guidance which specifies the computation, presentation and disclosure requirements for earnings per share of entities with publicly held common stock or potential common stock. The objective of basic EPS is to measure the performance of an entity over the reporting period by dividing income (loss) by the weighted average shares outstanding. The objective of diluted EPS is consistent with that of basic EPS, except that it also gives effect to all potentially dilutive common shares outstanding during the period. The following is a reconciliation of the basic and diluted earnings (loss) per share computation: Year Ended December 31, 2021 2020 2019 Net income (loss) for basic earnings per share $ 69,450,766 $ 56,342,010 $ (7,241,147 ) Less: Change in fair value of warrants 117,770 — 5,091,256 Net income (loss), adjusted for change in fair value of warrants for diluted earnings per share $ 69,332,996 $ 56,342,010 $ (12,332,403 ) Weighted-average shares 75,322,194 79,259,000 81,031,254 Effect of potential common shares 1,080,522 178,306 1,143,769 Weighted-average shares: diluted 76,402,716 79,437,306 82,175,023 Earnings (loss) per share: basic $ 0.92 $ 0.71 $ (0.09 ) Earnings (loss) per share: diluted $ 0.91 $ 0.71 $ (0.15 ) For the year ended December 31, 2021, not December 31, 2021 December 31, 2021, For the year ended December 31, 2020, not December 31, 2020 December 31, 2020, The Company incurred losses for the year ended December 31, 2019 Year Ended December 31, 2019 Stock Options 340,284 Stock-Settled Stock Appreciation Rights 1,666 Restricted Stock Units 525,741

Note 9 - Financial Instruments

Note 9 - Financial Instruments	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	9. 2016 On September 2, 2016, Note 7 November 16, 2016. December 31, 2021 December 31, 2020, December 31, 2021 ten The Company accounted for the Warrant in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain anti-dilution and cash settlement features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities. Accordingly, the Company classified the Warrant as a liability and reports its change in fair value in the consolidated statement of operations. On September 2, 2016, December 31, 2016. December 31, 2021 2020 As of December 31, 2021 no As of December 31, 2020 0.46%; no At December 31, 2021 no

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. Stockholders’ Equity On December 31, 2021 December 31, 2021 2020 On March 5, 2020, may December 31, 2021. December 31, 2021, On August 2, 2021, may December 31, 2023. fourth 2021. may may 10b5 1 December 31, 2021

Note 11 - Stock Compensation Pl

Note 11 - Stock Compensation Plans	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	11. Stock Compensation Plans The Company’s 2010 “2010 May 2010. 2010 May 17, 2011, 2010 February 2, 2012, 2010 April 25, 2012 May 23, 2017, 2010 2010 may not ten 2010 ten For the years ended December 31, 2021, 2020 2019 Stock Options Stock option awards provide holders the right to purchase shares of Common Stock at prices determined by the Compensation Committee, at the time of grant, and must have an exercise price equal to or in excess of the fair market value of the Company’s common stock at the date of grant. The fair value of options granted is estimated at the date of grant. Expected volatility has been estimated using a combination of the historical volatility of the Company's common stock and the historical volatility of a group of comparable companies’ common stock, both using historical periods equivalent to the options’ expected lives. The expected dividend yield assumption is based on the Company’s intent not A summary of the Company’s stock option activity is as follows: Weighted Weighted Aggregate Average Average Intrinsic Number of Exercise Remaining Life Value Options Price (in years) (in thousands) Outstanding at January 1, 2021 253,000 $ 9.78 Granted 50,000 6.57 Exercised — — Canceled/Expired (153,000 ) 12.53 Outstanding at December 31, 2021 150,000 $ 5.90 8.18 $ 243,000 Vested at December 31, 2021 150,000 $ 5.90 8.18 $ 243,000 Exercisable at December 31, 2021 150,000 $ 5.90 8.18 $ 243,000 As of December 31, 2021 December 31, 2021 2020 There were no stock options exercised during the year ended December 31, 2021. December 31, 2020 December 31, 2019, Restricted Stock Awards/Restricted Stock Units RSUs awarded to employees vest in equal annual installments over a two three one Weighted Average Number of Grant-Date RSUs Fair Value Outstanding at January 1, 2021 167,416 $ 5.86 Granted (1) 324,793 6.95 Vested and released (162,876 ) 5.82 Canceled/Expired — — Outstanding at December 31, 2021 (1) 329,333 $ 6.95 ( 1 As of December 31, 2021 December 31, 2021 2020 2019 December 31, 2021, 2020 2019

Note 12 - Income Taxes

Note 12 - Income Taxes	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12. Income Taxes The Company's provision (benefit) for income taxes comprises the following: For the year ended December 31, 2021 2020 2019 Current: Federal $ 19,211,782 $ 5,111,667 $ (663,114 ) State and local 513,753 447,965 143,455 Foreign 13,994 — — Total current provision (benefit) 19,739,529 5,559,632 (519,659 ) Deferred: Federal 89,947 11,375,962 (2,092,585 ) State and local 31,499 230,987 (325,032 ) Foreign — — — Total deferred provision (benefit) 121,446 11,606,949 (2,417,617 ) Total provision (benefit) $ 19,860,975 $ 17,166,581 $ (2,937,276 ) The Company’s deferred tax assets and liabilities comprise the following: As of December 31, 2021 2020 (1) Deferred income tax assets: Net operating losses $ 1,293,912 $ 1,293,842 Inventory 184,046 224,656 Reserves and accruals 741,684 725,875 Amortization of intangible assets 50,107 80,930 Share-based compensation 280,396 398,165 Deferred revenue 702,617 709,480 Lease liability 570,446 520,830 Other 267,050 191,174 Deferred income tax assets 4,090,258 4,144,952 Less: valuation allowance (1,022,191 ) (1,022,135 ) Deferred income tax assets, net of valuation allowance $ 3,068,067 $ 3,122,817 Deferred income tax liabilities: Amortization of goodwill (197,245 ) (199,172 ) Property, plant and equipment (156,289 ) (81,065 ) Other (291,926 ) (298,527 ) Deferred income tax asset, net $ 2,422,607 $ 2,544,053 ( 1 The recognition of a valuation allowance for deferred taxes requires management to make estimates and judgments about the Company’s future profitability which is inherently uncertain. The Company assesses all available positive and negative evidence to determine if its existing deferred tax assets are realizable on a more-likely-than- not December 31, 2021 not not not The benefit for income taxes differs from the expected amount calculated by applying the Company's statutory rate to the income or loss before benefit for income taxes as follows: As of December 31, 2021 2020 2019 Statutory federal income tax rate 21.0 % 21.0 % 21.0 % State and local taxes 0.5 % 0.7 % 1.3 % Change in fair value of common stock warrant — 1.0 % 10.5 % Section 162(m) limitation 0.5 % 0.5 % (6.0 )% Other 0.2 % 0.2 % 2.1 % Effective tax rate 22.2 % 23.4 % 28.9 % For the year ended December 31, 2021 162 December 31, 2020 162 A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, is as follows: For the year ended December 31, 2021 2020 2019 Balance at beginning of year $ 5,591,587 $ 5,649,188 $ 5,738,964 Tax positions related to the current and prior years: Additions 11,000 — — Reductions — (57,601 ) (89,776 ) Settlements — — — Lapses in applicable statutes of limitation — — — Balance at the end of the year $ 5,602,587 $ 5,591,587 $ 5,649,188 Included in the balance of unrecognized tax benefits as of December 31, 2021 December 31, 2021 December 31, 2020 no twelve December 31, 2021 The Company files federal income tax returns and income tax returns in various state and local tax jurisdictions. The federal tax years open to examination are 2018 2021 2017 2021

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	13. Commitments and Contingencies Operating lease commitments The Company leases its Corvallis, Oregon, facilities and office space under an operating lease which was signed on November 3, 2017 January 1, 2018. December 31, 2019, two one two three second 2019, first December 31, 2021. second 2021, second December 31, 2024. second second 2021. May 26, 2017 ten 31 62nd no Operating lease costs totaled $0.6 million and $0.7 million for the years ended December 31, 2021 2020 December 31, 2021 2020 December 31, 2021 The following is a maturity analysis of the Company's lease liabilities as of December 31, 2021 2022 577,473 2023 669,048 2024 678,627 2025 406,994 2026 409,971 Thereafter 165,916 Total undiscounted cash flows under operating leases 2,908,029 Less: Imputed interest (309,991 ) Present value of lease liabilities $ 2,598,038 As of December 31, 2021 Legal Proceedings From time to time, we may not Purchase Commitments In the course of our business, the Company regularly enters into agreements with third not December 31, 2021

Note 14 - Related Party Transac

Note 14 - Related Party Transactions	12 Months Ended
	Dec. 31, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	14. Related Party Transactions Board of Directors and Outside Counsel A former member of the Company’s Board of Directors who did not 2021 December 31, 2021, 2020 2019 December 31, 2021. Real Estate Leases On May 26, 2017, 31 62nd first sixty-three first six first sixty-fourth first second five December 31, 2021,

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the periods reported. The most significant estimates include the variables used in the calculation of fair value of warrants granted or issued by the Company, reported amounts of revenue, and the valuation of deferred tax assets. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary. Actual results could differ from these estimates.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The consolidated financial statements and related disclosures are presented in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and reflect the consolidated financial position, results of operations and cash flows for all periods presented.
Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents The Company considers all highly liquid investments with original maturities of three
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash and Cash Equivalents Cash and cash equivalents held in restricted accounts were available to pay interest, fees and principal related to the Term Loan (see Note 7 March 13, 2020, second 2020. December 31, 2021 2020. The following table reconciles cash, cash equivalents and restricted cash per the consolidated statements of cash flows to the consolidated balance sheet for each respective period: As of December 31, 2019 2018 Cash and cash equivalents $ 65,249,072 $ 100,652,809 Restricted cash - short-term 95,737,862 11,452,078 Restricted cash - long-term — 68,292,023 Cash, cash equivalents and restricted cash $ 160,986,934 $ 180,396,910
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk The Company has cash in bank accounts that exceeds the Federal Deposit Insurance Corporation insured limits. The Company has not no
Accounts Receivable [Policy Text Block]	Accounts Receivable Accounts receivable are recorded net of provisions for doubtful accounts. At December 31, 2021 2020 December 31, 2021 2020
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or net realizable value. The cost is determined using the first first may no
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant and Equipment Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation and amortization are provided on a straight-line method over the estimated useful lives of the various asset classes. The estimated useful lives are as follows: five three seven
Derivatives, Policy [Policy Text Block]	Warrant Liability The Company accounts for warrants in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain cash settlement features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Fair value is estimated using model-derived valuations. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities.
Revenue [Policy Text Block]	Revenue Recognition All of the Company’s revenue is derived from long-term contracts that span multiple years. The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers 606” Performance Obligations 606. December 31, 2021 Note 3 five two one Contract modifications may not The Company’s performance obligations are satisfied over time as work progresses or at a point in time. All of the Company’s revenue related to current research and development performance obligations is recognized over time, because the customer simultaneously receives and consumes the benefits provided by the services as the Company performs these services. The Company recognizes revenue related to these services based on the progress toward complete satisfaction of the performance obligation and measures this progress under an input method, which is based on the Company’s cost incurred relative to total estimated costs. Under this method, progress is measured based on the cost of resources consumed (i.e., cost of third third Contract Estimates Contract estimates are based on various assumptions to project the outcome of future events that often span multiple years. These assumptions include: labor productivity; the complexity of the work to be performed; external factors such as customer behavior and potential regulatory outcomes; and the performance of subcontractors, among other variables. The nature of the work required to be performed on many of the Company’s performance obligations and the estimation of total revenue and cost at completion are complex, subject to many variables and require significant judgment. The consideration associated with research and development services is variable as the total amount of services to be performed has not not A significant change in one Contract Balances may December 31, 2021 December 31, 2021 Remaining Performance Obligations not December 31, 2021 three
Lessee, Leases [Policy Text Block]	Leases The Company accounts for leases in accordance with ASC 842, Leases 842” Adoption of ASC 842 January 1, 2019, 842 first second 2019, first 842 January 1, 2019 The Company determines if an arrangement is a lease at inception. Leases with an initial term less than one not one Operating lease liabilities are recognized at the commencement date based on the present value of future minimum lease payments over the lease term. ROU assets are recognized based on the corresponding lease liabilities adjusted for qualifying initial direct costs, prepaid or accrued lease payments and unamortized lease incentives. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease. Lease terms may
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development expenses include costs directly and indirectly attributable to the conduct of research and development programs, and performance pursuant to certain customer contracts, including employee related costs, materials, supplies, depreciation on and maintenance of equipment, the cost of services provided by outside contractors, including services related to the Company’s clinical trials and facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred. Costs related to the acquisition of technology rights, for which development work is still in process, and that have no
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill The Company evaluates goodwill for impairment at least annually or as circumstances warrant. The impairment review process compares the fair value of the reporting unit in which goodwill resides to its carrying value. The Company operates as one one
Share-based Payment Arrangement [Policy Text Block]	Share-based Compensation Stock-based compensation expense for all share-based payment awards made to employees and directors is determined on the grant date; for option awards, fair value was estimated using the Black-Scholes model. These compensation costs are recognized net of an estimated forfeiture rate over the requisite service periods of the awards. Forfeitures are estimated on the date of the respective grant and revised if actual or expected forfeiture activity differs from original estimates. The fair value of cash-settled restricted stock unit ("RSU") awards is determined by the value of our common stock and is recognized based on the portion of the requisite service period satisfied as of each valuation date. The fair valuation of the cash-settled awards changes based on changes in our common stock price. The portion of cash-settled RSUs that is recognized based on service period is reflected in accrued expenses and other current liabilities in our consolidated balance sheet. Increases (or decreases) in accrued expenses result in adjustments to earnings for the associated valuation updates.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company recognizes income taxes utilizing the asset and liability method of accounting for income taxes. Under this method, deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities at enacted tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is established if it is more likely than not not may not fifty not
Stockholders' Equity, Policy [Policy Text Block]	Repurchase of shares When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, is recognized as a deduction from equity. The excess of the purchase price above par value of repurchased shares that are retired is presented as an increase to accumulated deficit (or a reduction of retained earnings, if any).
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) per Share Basic earnings per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period, assuming potentially dilutive common shares from option exercises, RSUs, warrants and other incentives had been issued and any proceeds received in respect thereof were used to repurchase common stock at the average market price during the period. The assumed proceeds used to repurchase common stock is the sum of the amount to be paid to the Company upon exercise of options and warrants and the amount of compensation cost attributed to future services not
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying value of cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximates fair value due to the relatively short maturity of these instruments. Common stock warrants which are classified as liabilities are recorded at their fair market value as of each reporting period. The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy: • Level 1 • Level 2 not • Level 3 third The Company uses model-derived valuations where certain inputs are unobservable to third 3. There were no 2021 2020 December 31, 2021 December 31, 2020 1 no 2 December 31, 2021 December 31, 2020 The following table presents changes in the liability-classified warrant measured at fair value using Level 3 Fair Value Measurements of Level 3 liability-classified warrant Warrant liability at December 31, 2020 $ 6,639,211 Decrease in fair value of warrant liability (117,770 ) Exercise of warrants — Warrant liability at December 31, 2021 $ 6,521,441
Commitments and Contingencies, Policy [Policy Text Block]	Loss Contingencies The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no
Segment Reporting, Policy [Policy Text Block]	Segment Information The Company is managed and operated as one not not one
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In December 2019, No. 2019 12, Simplifying the Accounting for Income Taxes December 15, 2020, first 2021 no

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Cash, Cash Equivalents and Investments [Table Text Block]	As of December 31, 2019 2018 Cash and cash equivalents $ 65,249,072 $ 100,652,809 Restricted cash - short-term 95,737,862 11,452,078 Restricted cash - long-term — 68,292,023 Cash, cash equivalents and restricted cash $ 160,986,934 $ 180,396,910
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair Value Measurements of Level 3 liability-classified warrant Warrant liability at December 31, 2020 $ 6,639,211 Decrease in fair value of warrant liability (117,770 ) Exercise of warrants — Warrant liability at December 31, 2021 $ 6,521,441

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	As of December 31, 2021 December 31, 2020 Raw materials $ 22,047 $ 2,628,153 Work in-process 17,453,358 15,415,425 Finished goods 2,034,974 2,221,941 Inventory $ 19,510,379 $ 20,265,519

Note 5 - Property, Plant and _2

Note 5 - Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	As of December 31, 2021 December 31, 2020 Leasehold improvements $ 2,420,028 $ 2,420,028 Computer equipment 511,062 532,125 Furniture and fixtures 377,859 377,859 Operating lease right-of-use asset 3,678,647 2,944,932 6,987,596 6,274,944 Less-accumulated depreciation (4,621,639 ) (4,170,954 ) Property, plant and equipment, net $ 2,365,957 $ 2,103,990

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Accrued Expenses and Other Current Liabilities [Table Text Block]	As of December 31, 2021 December 31, 2020 Deferred revenue $ 3,764,696 $ 3,280,947 Compensation 2,811,700 2,933,738 Other 558,362 486,158 Professional fees 527,026 251,824 Inventory 488,081 150,349 Lease liability, current portion 466,830 449,940 Vacation 379,720 405,176 Research and development vendor costs 256,397 327,606 Accrued expenses and other current liabilities $ 9,252,812 $ 8,285,738

Note 8 - Per Share Data (Tables

Note 8 - Per Share Data (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, 2021 2020 2019 Net income (loss) for basic earnings per share $ 69,450,766 $ 56,342,010 $ (7,241,147 ) Less: Change in fair value of warrants 117,770 — 5,091,256 Net income (loss), adjusted for change in fair value of warrants for diluted earnings per share $ 69,332,996 $ 56,342,010 $ (12,332,403 ) Weighted-average shares 75,322,194 79,259,000 81,031,254 Effect of potential common shares 1,080,522 178,306 1,143,769 Weighted-average shares: diluted 76,402,716 79,437,306 82,175,023 Earnings (loss) per share: basic $ 0.92 $ 0.71 $ (0.09 ) Earnings (loss) per share: diluted $ 0.91 $ 0.71 $ (0.15 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2019 Stock Options 340,284 Stock-Settled Stock Appreciation Rights 1,666 Restricted Stock Units 525,741

Note 11 - Stock Compensation _2

Note 11 - Stock Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Weighted Aggregate Average Average Intrinsic Number of Exercise Remaining Life Value Options Price (in years) (in thousands) Outstanding at January 1, 2021 253,000 $ 9.78 Granted 50,000 6.57 Exercised — — Canceled/Expired (153,000 ) 12.53 Outstanding at December 31, 2021 150,000 $ 5.90 8.18 $ 243,000 Vested at December 31, 2021 150,000 $ 5.90 8.18 $ 243,000 Exercisable at December 31, 2021 150,000 $ 5.90 8.18 $ 243,000
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Weighted Average Number of Grant-Date RSUs Fair Value Outstanding at January 1, 2021 167,416 $ 5.86 Granted (1) 324,793 6.95 Vested and released (162,876 ) 5.82 Canceled/Expired — — Outstanding at December 31, 2021 (1) 329,333 $ 6.95

Note 12 - Income Taxes (Tables)

Note 12 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	For the year ended December 31, 2021 2020 2019 Current: Federal $ 19,211,782 $ 5,111,667 $ (663,114 ) State and local 513,753 447,965 143,455 Foreign 13,994 — — Total current provision (benefit) 19,739,529 5,559,632 (519,659 ) Deferred: Federal 89,947 11,375,962 (2,092,585 ) State and local 31,499 230,987 (325,032 ) Foreign — — — Total deferred provision (benefit) 121,446 11,606,949 (2,417,617 ) Total provision (benefit) $ 19,860,975 $ 17,166,581 $ (2,937,276 )
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2021 2020 (1) Deferred income tax assets: Net operating losses $ 1,293,912 $ 1,293,842 Inventory 184,046 224,656 Reserves and accruals 741,684 725,875 Amortization of intangible assets 50,107 80,930 Share-based compensation 280,396 398,165 Deferred revenue 702,617 709,480 Lease liability 570,446 520,830 Other 267,050 191,174 Deferred income tax assets 4,090,258 4,144,952 Less: valuation allowance (1,022,191 ) (1,022,135 ) Deferred income tax assets, net of valuation allowance $ 3,068,067 $ 3,122,817 Deferred income tax liabilities: Amortization of goodwill (197,245 ) (199,172 ) Property, plant and equipment (156,289 ) (81,065 ) Other (291,926 ) (298,527 ) Deferred income tax asset, net $ 2,422,607 $ 2,544,053
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	As of December 31, 2021 2020 2019 Statutory federal income tax rate 21.0 % 21.0 % 21.0 % State and local taxes 0.5 % 0.7 % 1.3 % Change in fair value of common stock warrant — 1.0 % 10.5 % Section 162(m) limitation 0.5 % 0.5 % (6.0 )% Other 0.2 % 0.2 % 2.1 % Effective tax rate 22.2 % 23.4 % 28.9 %
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	For the year ended December 31, 2021 2020 2019 Balance at beginning of year $ 5,591,587 $ 5,649,188 $ 5,738,964 Tax positions related to the current and prior years: Additions 11,000 — — Reductions — (57,601 ) (89,776 ) Settlements — — — Lapses in applicable statutes of limitation — — — Balance at the end of the year $ 5,602,587 $ 5,591,587 $ 5,649,188

Note 13 - Commitments and Con_2

Note 13 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2022 577,473 2023 669,048 2024 678,627 2025 406,994 2026 409,971 Thereafter 165,916 Total undiscounted cash flows under operating leases 2,908,029 Less: Imputed interest (309,991 ) Present value of lease liabilities $ 2,598,038

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Jan. 01, 2019USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Restricted Cash and Cash Equivalents, Total		$ 0
Restricted Cash and Cash Equivalents, Total		$ 0
Receivables Percentage		98.00%	100.00%
Accounts Receivable, Allowance for Credit Loss, Ending Balance			$ 0
Accounts Receivable, Allowance for Credit Loss, Ending Balance			0
Contract with Customer, Receivable, after Allowance for Credit Loss, Current, Total		$ 2,200,000
Contract with Customer, Liability, Revenue Recognized		100,000	100,000
Revenue, Remaining Performance Obligation, Amount		$ 61,800,000
Number of Operating Segments		1
Number of Reporting Units		1
Cash and Cash Equivalents, at Carrying Value, Ending Balance		$ 103,138,819	$ 117,890,240	$ 65,249,072	$ 100,652,809
Number of Reportable Segments		1
Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents, at Carrying Value, Ending Balance		$ 100,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset	$ 2,900,000
Operating Lease, Liability, Total	3,300,000
Increase (Decrease) in Deferred Rent	$ 400,000
Laboratory Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)		5 years
Computer Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)		3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life (Year)		7 years

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash and cash equivalents	$ 103,138,819	$ 117,890,240	$ 65,249,072	$ 100,652,809
Restricted cash - short-term			95,737,862	11,452,078
Restricted cash - long-term			0	68,292,023
Cash, cash equivalents and restricted cash	$ 103,138,819	$ 117,890,240	$ 160,986,934	$ 180,396,910

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Change in Level 3 Liability (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Balance	$ 6,639,211
Decrease in fair value of warrant liability	(117,770)
Exercise of warrants	0
Balance	$ 6,521,441

Note 3 - Procurement Contract_2

Note 3 - Procurement Contracts and Research Agreements (Details Textual) $ in Thousands	Sep. 07, 2021USD ($)	Jan. 13, 2021USD ($)	Apr. 03, 2020USD ($)	Sep. 30, 2021USD ($)	Jun. 30, 2021USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	May 31, 2020USD ($)	Jul. 31, 2019USD ($)	Sep. 10, 2018USD ($)	May 13, 2011
Contract with Customer, Liability, Revenue Recognized						$ 100	$ 100
The 19C BARDA Contract [Member]
Number of Courses to Be Delivered										1,488,000
Number of Courses Stored As Vendor Managed Inventory										212,000
Government Contract, Value of Award						602,500
Government Contract, Base Period, Value of Award for Delivery and Support Activities						$ 51,700				$ 51,700
Base Period of Performance (Year)						5 years
Government Contract, Value, Payments Remaining Related to Exercised Options						$ 239,700
Government Contract, Value, Payments Currently Specified as Unexercised Options						$ 311,100
Government Contract, Option Exercised, Value of Consideration	$ 112,600
Base Period of Performance, Exercise of Options, Term (Year)						10 years
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Delivery of Courses										$ 11,100
Government Contract, Base Period, Number of Deliveries										35,700
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Manufacture of Courses										$ 8,000
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Advanced Development										32,000
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Supportive Procurement Activities										$ 600
Proceeds from Delivery of Courses						$ 11,100
Number of Courses Delivered						35,700
Proceeds from Other Base Period Activities						$ 13,800
Government Contract, Value of Unexercised Options, Supportive Procurement Activities						5,600
The 19C BARDA Contract [Member] | Transferred over Time [Member]
Contract with Customer, Liability, Revenue Recognized						4,800	7,500
The 19C BARDA Contract [Member] | Transferred at Point in Time [Member]
Proceeds from Delivery of Courses						112,500
Contract with Customer, Liability, Revenue Recognized							$ 112,600
The 19C BARDA Contract [Member] | IV TPOXX [Member]
Government Contract, Base Period, Number of Courses Manufactured										20,000
Government Contract, Value, Payments Related to Exercised Options, Funding of Post-Marketing Activities						3,600
Government Contract, Value, Payments Related to Unexercised Options, Delivery of Courses						$ 225,100
Number of Manufacturing Steps						2
The 19C BARDA Contract [Member] | IV BDS [Member]
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Manufacture of Courses										$ 3,200
Proceeds from the Manufacture of Courses						$ 3,200
Contract with Customer, Liability, Total						3,200
Government Contract, Value, Payments Currently Specified as Unexercised Options, Manufacture of Courses						$ 30,700
Government Contract, Number of Options for Manufacture of Product						3
Government Contract, Courses Manufactured Upon Exercise of Options						64,000
The 19C BARDA Contract [Member] | Oral TPOXX [Member]
Number of Courses to Be Delivered							726,140
Proceeds from Delivery of Courses						$ 112,500
Government Contract, Value, Payments Related to Exercised Options, Procurement of Raw Materials						225,100	$ 11,200
Government Contract, Value, Payments Related to Exercised Options, Delivery of Courses							213,900
Government Contract, Value, Payments Related to Exercised Options, Funding of Post-Marketing Activities						7,300	14,600
Government Contract, Value, Delivered and Invoiced						79,700
The 19C BARDA Contract [Member] | IV FDP [Member]
Government Contract, Value, Payments Currently Specified as Unexercised Options, Manufacture of Courses						$ 76,800
Government Contract, Number of Options for Manufacture of Product						3
Government Contract, Courses Manufactured Upon Exercise of Options						64,000
The 2011 BARDA Contract [Member]
Number of Courses to Be Delivered											1,700,000
Government Contract, Value of Award						$ 508,400
Proceeds from the Manufacture and Delivery of Courses						459,800
Proceeds from Reimbursements in Connection with Development and Supportive Activities						45,900
Amount Eligible to be Received for Reimbursements of Development and Supportive Activities						2,700
IC BARDA [Member]
Contract with Customer, Liability, Revenue Recognized						200	200
IC BARDA [Member] | Transferred at Point in Time [Member]
Contract with Customer, Liability, Revenue Recognized						0	400
Meridian Contract [Member] | Oral TPOXX [Member]
Government Contract, Value of Award		$ 33,000
Contract with Customer, Liability, Revenue Recognized						10,000
Government Contract, Term (Year)		5 years
Government Contract, Increased Value of Award						38,000
Government Contract, Firm Commitment not Subject to Option Exercise		$ 23,000
Canadian Contract [Member] | Meridian Medical Technologies [Member]
Contract with Customer, Liability, Revenue Recognized						12,700
Government Contract, Term (Year)			4 years
Other Commitment, Total			$ 14,000
Canadian Contract [Member] | Meridian Medical Technologies [Member] | Purchases from Q2 of 2020 [Member]
Contract with Customer, Liability, Revenue Recognized					$ 2,000
Canadian Contract [Member] | Meridian Medical Technologies [Member] | Purchases from Q3 of 2021 [Member]
Contract with Customer, Liability, Revenue Recognized				$ 2,000
Canadian Contract [Member] | Transferred at Point in Time [Member]
Contract with Customer, Liability, Revenue Recognized							2,300
The IV Formulation R & D Contract with BARDA [Member]
Contract with Customer, Liability, Revenue Recognized						800	1,400
Government Contract, Future Aggregate Research and Development Funding						500
The PEP Label Expansion R & D Contract with the Department of Defense [Member]
Government Contract, Value of Award								$ 26,000	$ 19,500
Contract with Customer, Liability, Revenue Recognized							$ 300
Government Contract, Future Aggregate Research and Development Funding						23,300
Government Contract, Initial Award									$ 12,400
The PEP Label Expansion R & D Contract with the Department of Defense [Member] | Transferred over Time [Member]
Contract with Customer, Liability, Revenue Recognized						$ 2,500

Note 4 - Inventory (Details Tex

Note 4 - Inventory (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Inventory Write-down, Net of Credits	$ 618,771	$ 0	$ 0
Inventory Write-down	$ 900,000

Note 4 - Inventory - Inventory

Note 4 - Inventory - Inventory (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Raw materials	$ 22,047	$ 2,628,153
Work in-process	17,453,358	15,415,425
Finished goods	2,034,974	2,221,941
Inventory	$ 19,510,379	$ 20,265,519

Note 5 - Property, Plant and _3

Note 5 - Property, Plant and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Depreciation, Depletion and Amortization, Total	$ 522,368	$ 529,814	$ 526,997

Note 5 - Property, Plant and _4

Note 5 - Property, Plant and Equipment - Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property, plant and equipment, gross	$ 6,987,596	$ 6,274,944
Less-accumulated depreciation	(4,621,639)	(4,170,954)
Property, plant and equipment, net	2,365,957	2,103,990
Other Assets [Member]
Operating lease right-of-use asset	3,678,647	2,944,932
Leasehold Improvements [Member]
Property, plant and equipment, gross	2,420,028	2,420,028
Computer Equipment [Member]
Property, plant and equipment, gross	511,062	532,125
Furniture and Fixtures [Member]
Property, plant and equipment, gross	$ 377,859	$ 377,859

Note 6 - Accrued Expenses - Acc

Note 6 - Accrued Expenses - Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred revenue	$ 3,764,696	$ 3,280,947
Compensation	2,811,700	2,933,738
Other	558,362	486,158
Professional fees	527,026	251,824
Inventory	488,081	150,349
Vacation	379,720	405,176
Research and development vendor costs	256,397	327,606
Accrued expenses and other current liabilities	9,252,812	8,285,738
Accrued Expenses and Other Current Liabilities [Member]
Lease liability, current portion	$ 466,830	$ 449,940

Note 7 - Debt (Details Textual)

Note 7 - Debt (Details Textual) - USD ($)	Mar. 13, 2020	Nov. 16, 2016	Sep. 02, 2016	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Repayments of Long-term Debt, Principal				$ 0	$ 85,913,459	$ 0
Gain (Loss) on Extinguishment of Debt, Total				$ 0	(4,981,461)	$ 0
Loan Agreement [Member] | Term Loan [Member] | OCM Strategic Credit SIGTEC Holdings, LLC [Member]
Repayments of Long-term Debt Including Interest	$ 87,200,000
Repayments of Long-term Debt, Principal	80,000,000
Repayments of Long-term Debt, Repayment Fee	4,000,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total	1,200,000
Repayments of Long-term Debt, Prepayment Premium	$ 1,900,000
Gain (Loss) on Extinguishment of Debt, Total					$ (5,000,000)
Proceeds from Issuance of Debt		$ 80,000,000
Debt Instrument, Term (Year)			4 years

Note 8 - Per Share Data (Detail

Note 8 - Per Share Data (Details Textual) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	29,873	1,124,585

Note 8 - Per Share Data - Recon

Note 8 - Per Share Data - Reconciliation of the Basic and Diluted Loss Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net income (loss)	$ 69,450,766	$ 56,342,010	$ (7,241,147)
Less: Change in fair value of warrants	117,770	0	5,091,256
Net income (loss), adjusted for change in fair value of warrants for diluted earnings per share	$ 69,332,996	$ 56,342,010	$ (12,332,403)
Weighted average shares outstanding: basic (in shares)	75,322,194	79,259,000	81,031,254
Effect of potential common shares (in shares)	1,080,522	178,306	1,143,769
Weighted-average shares: diluted (in shares)	76,402,716	79,437,306	82,175,023
Earnings (loss) per share: basic (in dollars per share)	$ 0.92	$ 0.71	$ (0.09)
Earnings (loss) per share: diluted (in dollars per share)	$ 0.91	$ 0.71	$ (0.15)

Note 8 - Per Share Data - Antid

Note 8 - Per Share Data - Antidilutive Securities Excluded from Computation (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Antidilutive securities (in shares)	29,873	1,124,585
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)			340,284
Stock Appreciation Rights (SARs) [Member]
Antidilutive securities (in shares)			1,666
Restricted Stock Units (Stock Settled) [Member]
Antidilutive securities (in shares)			525,741

Note 9 - Financial Instruments

Note 9 - Financial Instruments (Details Textual) $ / shares in Units, shares in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)shares	Dec. 31, 2020USD ($)shares	Sep. 02, 2016USD ($)$ / sharesshares
Warrants and Rights Outstanding | $	$ 6,521,441	$ 6,639,211
The 2016 Warrant [Member]
Class of Warrant or Right Outstanding, Common Stock Value Used to Determine Number of Shares Called | $			$ 4,000,000
Class of Warrant or Right Outstanding, Common Stock Price Per Share Used to Determine Number of Shares Called (in dollars per share) | $ / shares			$ 2.29
Class of Warrant or Right, Subscription Price of Warrants or Rights (in dollars per share) | $ / shares			1.50
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 1.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	1,000		2,700
Class of Warrant or Right, Exercised During Period (in shares) | shares	0	500
Warrants and Rights Outstanding, Term (Year)	10 years
Warrants and Rights Outstanding | $			$ 5,800,000
Warrants and Rights Outstanding, Measurement Input	6,500,000	6,600,000
The 2016 Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0121	0.0046
The 2016 Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0
The 2016 Warrant [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	4.7	5.7
The 2016 Warrant [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.55	0.80

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Aug. 02, 2021	Mar. 05, 2020
Capital Units, Authorized (in shares)	620,000,000
Common Stock, Shares Authorized (in shares)	600,000,000	600,000,000
Preferred Stock, Shares Authorized (in shares)	20,000,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	0	0
Preferred Stock, Shares Issued, Total (in shares)	0	0
Stock Repurchase Program, Authorized Amount				$ 50,000,000
Stock Repurchased During Period, Value	$ 26,021,519	$ 28,502,946
Share Repurchase Program Authorized 2020 [Member]
Stock Repurchased During Period, Shares (in shares)	3,200,000
Stock Repurchased During Period, Value	$ 21,500,000
New Repurchase Authorization [Member]
Stock Repurchase Program, Authorized Amount			$ 50,000,000
Stock Repurchased During Period, Shares (in shares)	600,000
Stock Repurchased During Period, Value	$ 4,500,000

Note 11 - Stock Compensation _3

Note 11 - Stock Compensation Plans (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	May 23, 2017	Apr. 25, 2012	May 17, 2011
Share-based Payment Arrangement, Expense	$ 1,300,000	$ 1,400,000	$ 2,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 258,000	383,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 87,000	$ 76,000
Stock Options [Member]
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)	0
Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	$ 1,400,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	10 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 6.95	$ 5.95	$ 5.84
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 900,000	$ 1,000,000	$ 1,600,000
Restricted Stock Units (RSUs) [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	1 year
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding Number to be Settled in Cash (in shares)	54,792
The 2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				8,500,000	4,500,000	2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years

Note 11 - Stock Compensation _4

Note 11 - Stock Compensation Plans - Stock Options Activity (Details) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Exercised (in shares)	0
Stock Options [Member]
Outstanding (in shares)	253,000
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 9.78
Granted (in shares)	50,000
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 6.57
Exercised (in shares)	0
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 0
Canceled/Expired (in shares)	(153,000)
Canceled/Expired, weighted average exercise price (in dollars per share) | $ / shares	$ 12.53
Outstanding (in shares)	150,000
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 5.90
Outstanding, weighted average remaining life (Year)	8 years 2 months 4 days
Outstanding, aggregate intrinsic value | $	$ 243
Vested (in shares)	150,000
Vested, weighted average exercise price (in dollars per share) | $ / shares	$ 5.90
Vested, weighted average remaining life (Year)	8 years 2 months 4 days
Vested, aggregate intrinsic value | $	$ 243
Exercisable (in shares)	150,000
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 5.90
Exercisable, weighted average remaining life (Year)	8 years 2 months 4 days
Exercisable, aggregate intrinsic value | $	$ 243

Note 11 - Stock Compensation _5

Note 11 - Stock Compensation Plans - Restricted Stock and Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Outstanding (in shares)		167,416
Outstanding, weighted average grant date fair value (in dollars per share)		$ 5.86
Granted (1) (in shares)	[1]	324,793
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 6.95	$ 5.95	$ 5.84
Vested and released (in shares)		(162,876)
Vested and released, weighted average grant date fair value (in dollars per share)		$ 5.82
Canceled/Expired (in shares)		0
Canceled/Expired, weighted average grant date fair value (in dollars per share)		$ 0
Outstanding (in shares)		329,333	167,416
Outstanding, weighted average grant date fair value (in dollars per share)		$ 6.95	$ 5.86
[1]	includes 54,792 awards which are expected to be settled in cash.

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	21.00%	21.00%
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$ 5,600,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total	$ 95,000	$ 65,000
Domestic Tax Authority [Member]
Open Tax Year	2018 2019 2020 2021
State and Local Jurisdiction [Member]
Open Tax Year	2017 2018 2019 2020 2021

Note 12 - Income Taxes - Compon

Note 12 - Income Taxes - Components of Income Tax Expense Benefit (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Federal	$ 19,211,782	$ 5,111,667	$ (663,114)
State and local	513,753	447,965	143,455
Foreign, current	13,994	0	0
Total current provision (benefit)	19,739,529	5,559,632	(519,659)
Federal	89,947	11,375,962	(2,092,585)
State and local	31,499	230,987	(325,032)
Foreign, deferred	0	0	0
Total deferred provision (benefit)	121,446	11,606,949	(2,417,617)
Total provision (benefit)	$ 19,860,975	$ 17,166,581	$ (2,937,276)

Note 12 - Income Taxes - Deferr

Note 12 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Net operating losses	$ 1,293,912	$ 1,293,842
Inventory	184,046	224,656
Reserves and accruals	741,684	725,875
Amortization of intangible assets	50,107	80,930
Share-based compensation	280,396	398,165
Deferred revenue	702,617	709,480
Lease liability	570,446	520,830
Other	267,050	191,174
Deferred income tax assets	4,090,258	4,144,952
Less: valuation allowance	(1,022,191)	(1,022,135)
Deferred income tax assets, net of valuation allowance	3,068,067	3,122,817
Amortization of goodwill	(197,245)	(199,172)
Property, plant and equipment	(156,289)	(81,065)
Other	(291,926)	(298,527)
Deferred income tax asset, net	$ 2,422,607	$ 2,544,053

Note 12 - Income Taxes - Effect

Note 12 - Income Taxes - Effective Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	21.00%	21.00%
State and local taxes	0.50%	0.70%	1.30%
Change in fair value of common stock warrant	0.00%	1.00%	10.50%
Section 162(m) limitation	0.50%	0.50%	(6.00%)
Other	0.20%	0.20%	2.10%
Effective tax rate	22.20%	23.40%	28.90%

Note 12 - Income Taxes - Unreco

Note 12 - Income Taxes - Unrecognized Tax Benefits Roll Forward (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Balance at beginning of year	$ 5,591,587	$ 5,649,188	$ 5,738,964
Additions	11,000	0	0
Reductions	0	(57,601)	(89,776)
Settlements	0	0	0
Lapses in applicable statutes of limitation	0	0	0
Balance at the end of the year	$ 5,602,587	$ 5,591,587	$ 5,649,188

Note 13 - Commitments and Con_3

Note 13 - Commitments and Contingencies (Details Textual) $ in Millions	Jan. 01, 2018	Jun. 30, 2021USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	May 26, 2017ft²
Operating Lease, Cost			$ 0.6	$ 0.7
Operating Lease, Payments			$ 0.6	$ 0.6
Operating Lease, Weighted Average Remaining Lease Term (Year)			4 years 7 months 6 days
Operating Lease, Weighted Average Discount Rate, Percent			4.53%
Purchase Commitment, Remaining Minimum Amount Committed			$ 20.1
Other Liabilities [Member]
Operating Lease, Liability, Noncurrent			$ 2.1
Two Years, Option Renewal Term [Member] | Facilities and Office Space in Corvallis Oregon [Member]
Lessee, Operating Lease, Number of Renewal Options	2
Lessee, Operating Lease, Renewal Term (Year)	2 years
Increase (Decrease) in Operating Right-of-use Assets		$ 0.7
Increase (Decrease) in Operating Lease Liability		$ 0.7
Three Years, Option RenewalTerm [Member] | Facilities and Office Space in Corvallis Oregon [Member]
Lessee, Operating Lease, Renewal Term (Year)	3 years
The New HQ Lease [Member] | MacAndrews and Forbes Incorporated [Member]
Lessee, Operating Lease, Term of Contract (Year)					10 years
Area of Real Estate Property (Square Foot) | ft²					3,200

Note 13 - Commitments and Con_4

Note 13 - Commitments and Contingencies - Maturity of Lease Liabilities (Details)	Dec. 31, 2021USD ($)
2022	$ 577,473
2023	669,048
2024	678,627
2025	406,994
2026	409,971
Thereafter	165,916
Total undiscounted cash flows under operating leases	2,908,029
Less: Imputed interest	(309,991)
Other Liabilities [Member]
Present value of lease liabilities	$ 2,598,038

Note 14 - Related Party Trans_2

Note 14 - Related Party Transactions (Details Textual)	May 26, 2017USD ($)ft²	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Outside Counsel [Member]
Legal Fees		$ 100,000	$ 500,000	$ 500,000
Accounts Payable, Related Parties		0
MacAndrews and Forbes Incorporated [Member] | The New HQ Lease [Member]
Area of Real Estate Property (Square Foot) | ft²	3,200
Monthly Rent During Initial Period	$ 25,333
Monthly Rent, Initial Period (Month)	63 months
Monthly Rent After Initial Period	$ 29,333
Monthly Facility Fee, Second Year	$ 3,333
Monthly Facility Fee, Yearly Rate Increase After Second Year	5.00%
Monthly Facility Fee, Final Year	$ 4,925
Operating Lease, Expense		$ 300,000